|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4874780A
(en)
*
|
1987-03-11 |
1989-10-17 |
Norsk Hydro A.S. |
Anticancer compounds
|
|
US5496928A
(en)
|
1990-06-07 |
1996-03-05 |
Banyu Pharmaceutical Co., Ltd. |
Endothelin antagonistic substance
|
|
TW217417B
(https=)
|
1991-12-04 |
1993-12-11 |
Manyu Seiyaku Kk |
|
|
EP0991660B8
(en)
|
1997-10-08 |
2006-04-05 |
Isotechnika,Inc. |
DEUTERATED and undeuterated CYCLOSPORINE ANALOGS AND THEIR USE AS IMMUNOMODULATING AGENTS
|
|
US7566452B1
(en)
|
1999-05-04 |
2009-07-28 |
New York University |
Cancer treatment with endothelin receptor antagonists
|
|
US6545048B1
(en)
|
1999-06-29 |
2003-04-08 |
California Institute Of Technology |
Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
|
|
GB0223854D0
(en)
|
2002-10-12 |
2002-11-20 |
Astrazeneca Ab |
Therapeutic treatment
|
|
JP2006508086A
(ja)
|
2002-10-24 |
2006-03-09 |
ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ |
固形腫瘍を予防および治療するための方法および組成物
|
|
US7713440B2
(en)
|
2003-10-08 |
2010-05-11 |
Lyotropic Therapeutics, Inc. |
Stabilized uncoated particles of reversed liquid crystalline phase materials
|
|
WO2006019637A2
(en)
|
2004-07-07 |
2006-02-23 |
The Regents Of The University |
An intelligent nanomedicine integrating diagnosis and therapy
|
|
US20080102451A1
(en)
|
2006-10-31 |
2008-05-01 |
Abbott Laboratories |
Companion diagnostic assays for endothelin receptor antagonists
|
|
WO2008088727A2
(en)
*
|
2007-01-12 |
2008-07-24 |
Concert Pharmaceuticals, Inc. |
Endothelin receptor antagonists
|
|
US9289426B2
(en)
|
2007-03-21 |
2016-03-22 |
University Of Pennsylvania |
Methods and compositions for treating solid tumors and enhancing tumor vaccines
|
|
US8303974B2
(en)
|
2007-06-11 |
2012-11-06 |
Edge Therapeutics, Inc. |
Drug delivery system for the prevention of cerebral vasospasm
|
|
CN102170908A
(zh)
|
2008-08-29 |
2011-08-31 |
莱顿大学医学中心附属莱顿教学医院 |
向个体的肿瘤引流淋巴结递送cd40激动剂
|
|
US20110053968A1
(en)
*
|
2009-06-09 |
2011-03-03 |
Auspex Pharmaceuticals, Inc. |
Aminopyrimidine inhibitors of tyrosine kinase
|
|
ES2543280T3
(es)
|
2009-08-10 |
2015-08-17 |
Board Of Regents, The University Of Texas System |
Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico
|
|
US20140341916A1
(en)
|
2011-10-28 |
2014-11-20 |
Genentech, Inc. |
Therapeutic combinations and methods of treating melanoma
|
|
TWI613215B
(zh)
|
2012-02-22 |
2018-02-01 |
再生元醫藥公司 |
抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
|
|
US10233277B2
(en)
|
2012-03-02 |
2019-03-19 |
The Governing Council Of The University Of Toronto |
Polymeric nanoparticles useful in theranostics
|
|
WO2014025837A1
(en)
|
2012-08-06 |
2014-02-13 |
Board Of Regents, The University Of Texas System |
Methods for treatment and prevention of tauopathies by inhibiting endothelin receptors
|
|
WO2015095404A2
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
|
AU2014364606A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
|
WO2015110593A1
(en)
|
2014-01-24 |
2015-07-30 |
Cecilia Naucler |
Use of endothelial receptor b inhibitors in prevention and treatment of human cytomegalovirus infection and cmv-related pathologies such as cardiovascular diseases and cancer
|
|
US9463201B2
(en)
|
2014-10-19 |
2016-10-11 |
M.G. Therapeutics Ltd |
Compositions and methods for the treatment of meibomian gland dysfunction
|
|
RS61152B2
(sr)
|
2015-05-12 |
2024-06-28 |
Hoffmann La Roche |
Terapeutski i dijagnostički postupci za lečenje raka
|
|
EP3763827A1
(en)
|
2015-05-29 |
2021-01-13 |
F. Hoffmann-La Roche AG |
Pd-l1 promoter methylation in cancer
|
|
JP7144935B2
(ja)
|
2015-05-29 |
2022-09-30 |
ジェネンテック， インコーポレイテッド |
癌のための治療方法及び診断方法
|
|
US10695400B2
(en)
|
2015-08-03 |
2020-06-30 |
Enb Therapeutics, Inc. |
Compositions and methods for treating cancers associated with ETBR activation
|
|
JP6821693B2
(ja)
|
2016-02-29 |
2021-01-27 |
ジェネンテック， インコーポレイテッド |
がんのための治療方法及び診断方法
|
|
WO2017165491A1
(en)
*
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
|
|
AU2019206652B2
(en)
|
2018-01-12 |
2024-11-14 |
Enb Therapeutics, Inc. |
Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
|
|
EP3746110A4
(en)
|
2018-03-30 |
2022-03-02 |
ENB Therapeutics, Inc. |
ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS AND USES
|
|
CN114423425A
(zh)
|
2019-07-17 |
2022-04-29 |
Enb治疗公司 |
通过使用内皮素b受体拮抗剂治疗尿路上皮癌和肾癌
|
|
US20200289495A1
(en)
|
2020-03-24 |
2020-09-17 |
Enb Therapeutics, Inc. |
Methods of inhibiting endothelin b receptor expressing tumor metastases
|
|
US20200268829A1
(en)
|
2020-03-24 |
2020-08-27 |
Enb Therapeutics, Inc. |
Methods and compositions for inhibiting metastases of an endothelin b receptor expressing cancer
|